Role of topoisomerases in pediatric high grade osteosarcomas: TOP2A gene is one of the unique molecular biomarkers of chemoresponse

Cancers

Volumn 5, Issue 2, 2013, Pages 662-675

  Nguyen, Aurelia ^a,b   Lasthaus, Christelle ^a,b   Guerin, Eric ^a,b   Marcellin, Luc ^a   Pencreach, Erwan ^a,b   Gaub, Marie Pierre ^a,b   Guenot, Dominique ^a   Entz Werle, Natacha ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Chemoresponse; Osteosarcoma; Topoisomerase

Indexed keywords

DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TOPOISOMERASE IIALPHA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AMPLICON; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOSENSITIVITY; CHILD; CHROMOSOME 17Q; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG RESPONSE; EVENT FREE SURVIVAL; GENE FUNCTION; GENE LOCUS; GENE TARGETING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; OSTEOSARCOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PROTEIN EXPRESSION; PROTO ONCOGENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; TOP1; TOP2B; TOPOISOMERASE IIALPHA GENE; TUMOR BIOPSY; TUMOR GENE;

EID: 84878861165     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5020662     Document Type: Article

References (28)

1. Huvos, A.G. Bone Tumors, Diagnosis, Treatment, and Prognosis, 2nd ed.; W.B. Saunders: Philadelphia, PA, USA, 1991; pp. 85-155, 343-393.
2. Huvos, A.G.; Rosen, G.; Marcove, R.C. Primary osteogenic sarcoma. Pathologic aspects in twenty patients after treatment with chemotherapy, in bloc resection and prosthetic bone replacement. Arch. Pathol. Lab. Med. 1977, 101, 14-18.
3. Le Deley, M.C.; Guinebretière, J.M.; Gentet, J.C.; Pacquement, H.; Pichon, F.; Marec-Bérard, P.; Entz-Werlé, N.; Schmitt, C.; Brugières, L.; Vanel, D.; et al. Société Française d'Oncologie Pédiatrique (SFOP). SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur. J. Cancer 2007, 43, 752-761.
4. Lau, C.C. Molecular classification of osteosarcoma. Cancer Treat. Res. 2009, 152, 59-65.
5. Jarvinen, T.A.; Tanner, M.; Barlund, M.; Borg, A.; Isola, J. Characterization of topoisomerase II a gene amplification and deletion in breast cancer. Genes Chromosom. Cancer 1999, 26, 142-150.
6. Feister, H.A.; Swartz, D.; Odgren, P.R.; Holden, J.; Hock, J.M.; Onyia, J.; Bidwell, J.P. Topoisomerase II expression in osseous tissue. J. Cell Biochem. 1997, 67, 451-465.
7. Feister, H.A.; Onyia, J.E.; Miles, R.R.; Yang, X.; Galvin, R.; Hock, J.M.; Bidwell, J.P. The expression of the nuclear matrix proteins NuMA, topoisomerase II-alpha, and-beta in bone and osseous cell culture: Regulation by parathyroid hormone. Bone 2000, 26, 227-234.
8. Turley, H.; Comley, M.; Houlbrook, S.; Nozaki, N.; Kikuchi, A.; Hickson, I.D.; Gatter, K.; Harris, A.L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br. J. Cancer 1997, 75, 1340-1346.
9. Harisi, R.; Dudás, J.; Timár, F.; Pogány, G.; Timár, J.; Kovalszky, I.; Szendroi, M.; Jeney, A. Invasive growth and topoisomerase-switch induced by tumorous extracellular matrix in osteosarcoma cell culture. Cell Biol. Int. 2005, 29, 959-967.
10. Christiansen, M.; Kveiborg, M.; Kassem, M.; Clark, B.F.; Rattan, S.I. CBFA1 and topoisomerase I mRNA levels decline during cellular aging of human trabecular osteoblasts. J. Gerontol. A Biol. Sci. Med. Sci. 2000, 55, B194-B200.
11. Wang, J.C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65, 635-692.
12. Entz-Werle, N.; Schneider, A.; Kalifa, C.; Voegeli, A.C.; Tabone, M.D.; Marec-Berard, P.; Marcellin, L.; Pacquement, H.; Terrier, P.; Boutard, P.; et al. Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping. Br. J. Cancer 2003, 88, 1925-1931.
13. Entz-Werlé, N.; Stoetzel, C.; Berard-Marec, P.; Kalifa, C.; Brugieres, L.; Pacquement, H.; Schmitt, C.; Tabone, M.D.; Gentet, J.C.; Quillet, R.; et al. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int. J. Cancer 2005, 117, 349-355.
14. Entz-Werle, N.; Lavaux, T.; Metzger, N.; Stoetzel, C.; Lasthaus, C.; Marec, P.; Kalifa, C.; Brugieres, L.; Pacquement, H.; Schmitt, C.; et al. Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia 2007, 9, 678-688.
15. Jarvinen, T.A.; Tanner, M.; Rantanen, V.; Barlund, V.; Barlund, A.; Borg, A.; Grenman, S.; Isola, J. Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 2000, 156, 839-847.
16. Knoop, A.S.; Knudsen, H.; Balslev, E. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2005, 23, 7483-7490.
17. Nielsen, K.V.; Ejlertsen, B.; Moller, S. The value of TOP2A gene copy number ariation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol. 2008, 47, 725-734.
18. O'Malley, F.P.; Chia, S.; Tu, D. Topoisomerase II a and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl. Cancer Inst. 2009, 101, 644-650.
19. Somers, G.R.; Ho, M.; Zielenska, M.; Squire, J.A.; Thorner, P.S. HER2 amplification and overexpression is not present in pediatric osteosarcoma: A tissue microarray study. Pediatr. Dev. Pathol. 2005, 8, 525-532.
20. Rakesh, K.V.; Gupta, N.; Kakkar, N.; Sharma, S.C. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma. J. Cancer Res. Ther. 2006, 2, 20-23.
21. Chen, Y.; Yang, Y.; Yuan, Z.; Wang, C.; Shi, Y. Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry. Oncol. Lett. 2012, 3, 1011-1016.
22. Ma, Y.; Ren, Y.; Han, E.Q.; Li, H.; Chen, D.; Jacobs, J.J.; Gitelis, S.; O'Keefe, R.J.; Konttinen, Y.T.; Yin, G.; et al. Inhibition of the Wnt-ß-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem. Biophys. Res. Commun. 2013, 431, 274-279.
23. Qu, J.T.; Wang, M.; He, H.L.; Tang, Y.; Ye, X.J. The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: A meta-analysis and systemic review. J. Cancer Res. Clin. Oncol. 2012, 138, 819-825.
24. Romero, A.; Caldés, T.; Díaz-Rubio, E.; Martín, M. Topoisomerase 2 alpha: A real predictor of anthracycline efficacy? Clin. Transl. Oncol. 2012, 14, 163-168.
25. Olsen, K.E.; Knudsen, H.; Rasmussen, B.B.; Balslev, E.; Knoop, A.; Ejlertsen, B.; Nielsen, K.V.; Schönau, A.; Overgaard, J.; Danish Breast Cancer Co-operative Group. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol. 2004, 43, 35-42.
26. Romero, A.; Martín, M.; Cheang, M.C.; López García-Asenjo, J.A.; Oliva, B.; He, X.; de la Hoya, M.; García Sáenz, J. Á.; Arroyo Fernández, M.; Díaz Rubio, E.; et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Am. J. Pathol. 2011, 178, 1453-1460.
27. GDB Homepage. Avaible online: http://www.gdb.org/ (accessed on 5 April 2013).
28. A New Gene Map of the Human Genome. Available online: http://www.ncbi.nlm.nih.gov/genemap99/ (accessed on 5 April 2013).